You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Relapsed-Refractory Leukemia

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse Trial in Xuzhou (anti Tim-3/CD123 CAR-T cell therapy)

Recruiting
  • Acute Myeloid Leukemia Refractory
  • Acute Myeloid Leukemia, in Relapse
  • anti Tim-3/CD123 CAR-T cell therapy
  • Xuzhou, Jiangsu, China
    Kailin Xu
Nov 4, 2023

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Relapsed/Refractory Chronic Lymphocytic Leukemia Trial in Tianjin (GNC-035)

Not yet recruiting
  • Relapsed/Refractory Chronic Lymphocytic Leukemia
  • Tianjin, Tianjin, China
    Institute of Hematology and Blood Diseases Hospital, Chinese Aca
Jul 13, 2023

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission Trial in São Paulo (Bortezomib)

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • Acute Lymphoblastic Leukemia With Failed Remission
  • São Paulo, SP, Brazil
    Instituto do Cancer do Estado de Sao Paulo
Sep 12, 2023

Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Tumor (BPDCN), Relapse Leukemia Trial in Taiyuan (CD123 targeted

Recruiting
  • Acute Myeloid Leukemia
  • +3 more
  • CD123 targeted CAR-NK cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Aug 28, 2023

PET-CT Imaging in Relapsed/Refractory Acute Leukemias

Not yet recruiting
  • B Cell
  • +2 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Aug 4, 2023

    Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory Trial (CB-012)

    Not yet recruiting
    • Acute Myeloid Leukemia, in Relapse
    • Acute Myeloid Leukemia Refractory
    • (no location specified)
    Nov 9, 2023

    Acute Myeloid Leukemia Trial in Beijing (Ven+CAG)

    Recruiting
    • Acute Myeloid Leukemia
    • Beijing, Beijing, China
      Peking University People's Hospital
    Jun 23, 2023

    Acute Myeloid Leukemia (Relapsed/Refractory) Trial in Suzhou (Selinexor, Chidamide)

    Recruiting
    • Acute Myeloid Leukemia (Relapsed/Refractory)
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Jul 16, 2023

    Relapsed/Refractory Acute Myeloid Leukemia Trial in Hangzhou (B7-H3 target, CAR gene modified gdT cell injection)

    Recruiting
    • Relapsed/Refractory Acute Myeloid Leukemia
    • B7-H3 target, CAR gene modified gdT cell injection
    • Hangzhou, Zhejiang, China
      The First Affiliated Hospital， Zhejiang University School of Med
    Feb 15, 2023

    Relapsed and/or Refractory Multiple Myeloma, Plasma Cell Leukemia in Relapse Trial in Shanghai (Biological)

    Recruiting
    • Relapsed and/or Refractory Multiple Myeloma
    • Plasma Cell Leukemia in Relapse
    • Biological
    • Shanghai, Shanghai, China
      Shanghai Tongji Hospital
    May 29, 2023

    B Precursor Acute Lymphoblastic Leukemia, Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia Trial (Blinatumomab)

    Not yet recruiting
    • B Precursor Acute Lymphoblastic Leukemia
    • Relapsed/Refractory B Precursor Acute Lymphoblastic Leukemia
    • (no location specified)
    Sep 25, 2023

    B-cell Acute Lymphoblastic Leukemia Trial (CD19-CAR_Lenti_ALLO)

    Not yet recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • (no location specified)
    Oct 10, 2023

    B-cell Acute Lymphoblastic Leukemia Trial (HY004, Cyclophosphamide, Fludarabine Phosphate)

    Not yet recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • HY004
    • +2 more
    • (no location specified)
    Aug 18, 2023

    T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma Trial (CD7-CART01)

    Not yet recruiting
    • T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
    • CD7-CART01
    • (no location specified)
    Sep 26, 2023

    Relapsed/Refractory AML Trial in Suzhou (Selinexor, Homoharringtonine, Cytarabine)

    Not yet recruiting
    • Relapsed/Refractory AML
    • Suzhou, Jiangsu, China
      The First Affiliated Hospital of Soochow University
    Mar 28, 2023

    Relapsed or Refractory Acute Myeloid Leukemia Trial in Taiyuan (Selinexor, Homoharringtonine, Daunorubicin)

    Recruiting
    • Relapsed or Refractory Acute Myeloid Leukemia
    • Taiyuan, Shanxi, China
      Tao Wang
    Feb 9, 2023

    Refractory B-cell Acute Lymphoblastic Leukemia Trial in Houston (Mosunetuzumab)

    Not yet recruiting
    • Refractory B-cell Acute Lymphoblastic Leukemia
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 18, 2023

    B-cell Acute Lymphoblastic Leukemia Trial in Hefei (QH103 Cell Injection, Fludarabine, Cyclophosphamide)

    Recruiting
    • B-cell Acute Lymphoblastic Leukemia
    • QH103 Cell Injection
    • +2 more
    • Hefei, Anhui, China
      Anhui Provincial Hospital
    Sep 21, 2023

    Relapsed/Refractory Acute Myeloid Leukemia Trial in Hefei (gdT cell injection targeting B7-H3 chimeric antigen receptor)

    Recruiting
    • Relapsed/Refractory Acute Myeloid Leukemia
    • gdT cell injection targeting B7-H3 chimeric antigen receptor
    • Hefei, Anhui, China
      PersonGen Anke Cellular Therapeutice Co., Ltd.
    Jan 31, 2023

    Acute Myeloid Leukemia, MDS Trial in United States (GLB-001)

    Recruiting
    • Acute Myeloid Leukemia
    • Myelodysplastic Syndromes
    • Duarte, California
    • +3 more
    Nov 21, 2023

    Relapsed/Refractory Large Granular T Lymphocytic Leukemia Trial in Zhoukou, Tianjin (Linperlisib)

    Not yet recruiting
    • Relapsed/Refractory Large Granular T Lymphocytic Leukemia
    • Zhoukou, Henan, China
    • +1 more
    Dec 22, 2022

    Acute Myeloid Leukemia, High-Risk and Very High-Risk MDS Trial (SGR-2921)

    Not yet recruiting
    • Acute Myeloid Leukemia
    • High-Risk and Very High-Risk Myelodysplastic Syndromes
    • (no location specified)
    Jul 25, 2023

    AML, AML With Mutated NPM1, Hematologic Malignancy Trial (Ziftomenib, Fludarabine, Idarubicin)

    Not yet recruiting
    • AML
    • +11 more
    • (no location specified)
    Aug 14, 2023

    Relapsed/Refractory Multiple Myeloma, Plasma Cell Leukemia Trial (CAR-T (CAR-GPRC5D))

    Not yet recruiting
    • Relapsed/Refractory Multiple Myeloma
    • Plasma Cell Leukemia
    • CAR-T (CAR-GPRC5D)
    • (no location specified)
    Feb 26, 2023